Scribe Therapeutics
Main focus: Development of CasX for therapeutic use in genetic diseases
Company stage: Pre-clinical
Diseases: Amyotrophic lateral sclerosis (ALS), otherwise undisclosed
Genome editing tool: CRISPR-CasX
Funding stage: Private
Location: San Francisco Bay Area, California, United States
Website: https://www.scribetx.com/
Partners: Biogen
Scribe Therapeutics develops novel Cas variants, in particular the CasX enzyme, for the treatment of genetic diseases. The company has yet to disclose its pre-clinical pipeline. However, it has unveiled a collaboration with Biogen focusing on ALS.